DrugPatentWatch Database Preview

ALTACE Drug Profile

When do Altace patents expire, and when can generic versions of Altace launch?

Altace is a drug marketed by King Pharms Llc and King Pfizer and is included in two NDAs. There is one patent protecting this drug.

This drug has forty-seven patent family members in thirty-two countries.

The generic ingredient in ALTACE is ramipril. There are nineteen drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the ramipril profile page.

Summary for ALTACE

International Patents:	47
US Patents:	1
Applicants:	2
NDAs:	2
Suppliers / Packagers:	1
Bulk Api Vendors:	79
Clinical Trials:	15
Patent Applications:	5,995
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for ALTACE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ALTACE
DailyMed Link:	ALTACE at DailyMed

Drug patent expirations by year for ALTACE

Recent Clinical Trials for ALTACE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Wake Forest University Health Sciences	Phase 2
National Cancer Institute (NCI)	Phase 2
Ferrer Internacional S.A.	Phase 2

See all ALTACE clinical trials

Recent Litigation for ALTACE

Identify potential future generic entrants

District Court Litigation

Case Name	Date
Aventis Pharmaceuticals Inc. v. Barr Laboratories Inc.	2006-05-02
Boehringer Ingelheim International GMBH v. Barr Laboratories, Inc.	2005-09-26
Aventis Pharma Deutschland GmbH v. Lupin Ltd.	2005-07-15

See all ALTACE litigation

Pharmacology for ALTACE

Drug Class	Angiotensin Converting Enzyme Inhibitor
Mechanism of Action	Angiotensin-converting Enzyme Inhibitors

Synonyms for ALTACE

(2 S ,3 aS ,6 aS )-1[( S )-N-[( S )-1-Carboxy-3-phenylpropyl] alanyl] octahydrocyclopenta [ b ]pyrrole-2-carboxylic acid, 1-ethyl ester
(2S-(1(R(R)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)octahydrocyclopenta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-((S)-2-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)octahydrocyclopenta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid
(2s,3as,6as)-1-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-octahydrocyclopenta[b]p
(2S,3aS,6aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester
(2S,3aS,6aS)-1-((S)-N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrol-2-carbonsaeure
(2S,3aS,6aS)-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-[(2S)-2-[[(1S)-1-ethoxycarbonyl-3-phenyl-propyl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[d]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydrocyclopenta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (non-preferred name)
(2s,3as,6as)-1-[(s)-2-((s)-1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]
(2s,3as,6as)-1((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic
[2s,3as,6as]-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopen
[2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid
1-[2-(1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]pyrrole-2-carboxylic acid(Ramipril)
126613-39-6
333R195
87333-19-5
88094-EP2270011A1
88094-EP2272841A1
88094-EP2277879A1
88094-EP2287165A2
88094-EP2287166A2
88094-EP2292620A2
88094-EP2298742A1
88094-EP2298776A1
88094-EP2298779A1
88094-EP2301923A1
88094-EP2301931A1
88094-EP2301936A1
88094-EP2305648A1
AB0008490
AB00698339_09
AB00698339_10
AB00698339-07
AB00698339-08
AB07503
AB2000297
AC-1347
AC1NSFPR
Acovil
AKOS005622534
Altace (TN)
AN-15038
B2208
BBL033964
BC205360
BDBM50084681
BIDD:GT0803
BSPBio_003347
C23H32N2O5
Carasel
Cardace
CAS-87333-19-5
CCG-100833
CHEBI:8774
CHEMBL1168
CPD000466386
CS-2270
CTK8G2889
Cyclopenta(b)pyrrole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2S-(1(R(R)),2alpha,3abeta,6abeta))-
Cyclopenta(b)pyrrole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2S(1(R(R)),2alpha,3abeta,6abeta))-
D00421
DB00178
Delix
DSSTox_CID_3551
DSSTox_GSID_23551
DSSTox_RID_77077
DTXSID8023551
GTPL6339
HDACQVRGBOVJII-JBDAPHQKSA-N
HMS2051E04
HMS2090L11
HMS2093M10
HMS2231M05
HMS3259J07
HMS3715M16
HOE 498
Hoe-498
HOE498
HY-B0279
Hypren
Hytren
J90014
KBio2_002504
KBio2_005072
KBio2_007640
KBio3_002849
KBioGR_001858
KBioSS_002512
KS-1103
L35JN3I7SJ
Lostapres
LS-58199
MCULE-5386328912
MFCD00865775
MLS000759523
MLS001216547
MLS001423965
MolPort-001-736-571
N-(1S-carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3S-carboxylic Acid
Naprix
NC00083
NC00627
NCGC00016955-01
NCGC00178127-01
NCGC00178127-02
NE42859
NPD2431
NSC-758933
NSC758933
Pharmakon1600-01505214
Pramace
Pramace (discontinued)
Prilace
Quark
Ramace
ramipril
Ramipril (Altace)
Ramipril (USP/INN)
Ramipril [USAN:INN:BAN]
Ramipril [USAN:USP:INN:BAN]
Ramipril, >=98% (HPLC)
Ramipril, British Pharmacopoeia (BP) Reference Standard
Ramipril, European Pharmacopoeia (EP) Reference Standard
Ramipril, Pharmaceutical Secondary Standard; Certified Reference Material
Ramipril, United States Pharmacopeia (USP) Reference Standard
Ramiprilum
Ramiprilum [Latin]
Ramipro
Ramipro;Tritace;Prilace;Altace
s1793
SAM001246757
SAM002699899
SBI-0206728.P001
SC-17348
SCHEMBL16059
SMR000466386
Spectrum_001958
SPECTRUM1505214
Spectrum3_001794
Spectrum4_001269
Spectrum5_001721
SR-05000001908
SR-05000001908-1
SR-05000001908-2
STK801937
Tox21_110708
Tox21_110708_1
Triatec
Tritace
UNII-L35JN3I7SJ
Unipril
Vesdil
Z1946144927
ZINC3798757

US Patents and Regulatory Information for ALTACE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Request a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
King Pharms Llc	ALTACE	ramipril	CAPSULE;ORAL	019901-001	Jan 28, 1991	AB	RX	Yes	No	See Pricing	See Pricing				See Pricing
King Pfizer	ALTACE	ramipril	TABLET;ORAL	022021-003	Feb 27, 2007		DISCN	Yes	No	See Pricing	See Pricing				See Pricing
King Pharms Llc	ALTACE	ramipril	CAPSULE;ORAL	019901-004	Jan 28, 1991	AB	RX	Yes	Yes	See Pricing	See Pricing				See Pricing
King Pfizer	ALTACE	ramipril	TABLET;ORAL	022021-004	Feb 27, 2007		DISCN	Yes	No	See Pricing	See Pricing				See Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for ALTACE

Subscribe to access the full database, or Request a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
King Pharms Llc	ALTACE	ramipril	CAPSULE;ORAL	019901-002	Jan 28, 1991	See Pricing	See Pricing
King Pfizer	ALTACE	ramipril	TABLET;ORAL	022021-003	Feb 27, 2007	See Pricing	See Pricing
King Pfizer	ALTACE	ramipril	TABLET;ORAL	022021-002	Feb 27, 2007	See Pricing	See Pricing
King Pfizer	ALTACE	ramipril	TABLET;ORAL	022021-001	Feb 27, 2007	See Pricing	See Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for ALTACE

Subscribe to access the full database, or Request a Trial
Country	Patent Number	Estimated Expiration
Spain	2246894	See Pricing
Australia	2009200746	See Pricing
China	1268331	See Pricing
South Korea	20120055730	See Pricing
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for ALTACE

Subscribe to access the full database, or Request a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0265685	C980030	Netherlands	See Pricing	PRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919
0265685	99C0001	Belgium	See Pricing	PRODUCT NAME: FELODIPINUM + RAMIPRILUM; NATL. REGISTRATION NO/DATE: 354 IS 373 F 3 19981103; FIRST REGISTRATION: SE 13597 19970919
0265685	SPC/GB98/047	United Kingdom	See Pricing	PRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description